Cargando…

AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR

Angiogenesis plays an important role in neoplastic transformation and progression as well as in the metastasis process of most human cancers. Herein, we identified AL3810 as a novel and orally bioavailable small molecular inhibitor with potent inhibitory activity against multiple tyrosine kinases in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yuanfeng, Chen, Yi, Tong, Linjiang, Xie, Hua, Wen, Weiwei, Zhang, Jie, Xi, Yong, Shen, Yanyan, Geng, Meiyu, Wang, Yuanyuan, Jiang, Hualiang, Luo, Cheng, Lin, Liping, Ding, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823425/ https://www.ncbi.nlm.nih.gov/pubmed/22304225 http://dx.doi.org/10.1111/j.1582-4934.2012.01541.x

Ejemplares similares

Is PDGFR an important target for E-3810?
por: Damia, Giovanna, et al.
Publicado: (2012)

Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
por: Liang, Donglou, et al.
Publicado: (2017)

Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma
por: Jiang, Honglei, et al.
Publicado: (2017)

Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression
por: Berndsen, Robert H., et al.
Publicado: (2019)

Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810
por: Colzani, Mara, et al.
Publicado: (2014)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling
por: Su, Min, et al.
Publicado: (2016)

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment
por: Friedman, Adam A., et al.
Publicado: (2015)

VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
por: Patten, Steven G, et al.
Publicado: (2010)

Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis
por: Bi, Yan-Ling, et al.
Publicado: (2017)

VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity
por: Shang, Pengzhao, et al.
Publicado: (2021)

VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not PDGF-BB/PDGFR-β play important roles in promoting immature and inflammatory intraplaque angiogenesis
por: Mao, Yang, et al.
Publicado: (2018)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

Sunitinib-Containing Carborane Pharmacophore with the Ability to Inhibit Tyrosine Kinases Receptors FLT3, KIT and PDGFR-β, Exhibits Powerful In Vivo Anti-Glioblastoma Activity
por: Alamón, Catalina, et al.
Publicado: (2020)

Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents
por: Zhang, Lin, et al.
Publicado: (2017)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules
por: Ho, Shu-Yi, et al.
Publicado: (2020)

Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer
por: Rho, Seung Bae, et al.
Publicado: (2021)

Methanolic extract of Euchelus asper exhibits in-ovo anti-angiogenic and in vitro anti-proliferative activities
por: Agrawal, Sweta, et al.
Publicado: (2017)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
por: Liu, Guihong, et al.
Publicado: (2021)

Opticin: a potent anti-angiogenic/antiproliferative agent for breast cancer therapy
por: Sneddon, SF, et al.
Publicado: (2010)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
por: Romagnoli, Simone, et al.
Publicado: (2021)

VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer
por: Wei, Xie, et al.
Publicado: (2016)

Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer
por: Bajbouj, Khuloud, et al.
Publicado: (2022)

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma
por: Canter, Robert J, et al.
Publicado: (2014)

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
por: Chu, Jie Sheng, et al.
Publicado: (2013)

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome
por: Estevez-Garcia, Purificacion, et al.
Publicado: (2012)

Characterisation of Novel Angiogenic and Potent Anti-Inflammatory Effects of Micro-Fragmented Adipose Tissue
por: Guo, Baoqiang, et al.
Publicado: (2021)

Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
por: Wong, Jocelyn P., et al.
Publicado: (2016)

A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated
por: Li, Jinyang, et al.
Publicado: (2021)

A Phase Ib Study of Lucitanib (AL3810) in a Cohort of Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma
por: Zhang, Yang, et al.
Publicado: (2022)

Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway
por: Ai, Nana, et al.
Publicado: (2018)

Acidic pH reduces VEGF-mediated endothelial cell responses by downregulation of VEGFR-2; relevance for anti-angiogenic therapies
por: Faes, Seraina, et al.
Publicado: (2016)

Nanocarrier Drug Conjugates Exhibit Potent Anti-Naegleria fowleri and Anti-Balamuthia mandrillaris Properties
por: Siddiqui, Ruqaiyyah, et al.
Publicado: (2023)

Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-β, and CDK4 in canine urothelial carcinoma
por: Setyo, Laura C., et al.
Publicado: (2023)

Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer
por: Sikander, Mohammed, et al.
Publicado: (2016)

Notch regulates the angiogenic response via induction of VEGFR-1
por: Funahashi, Yasuhiro, et al.
Publicado: (2010)

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
por: Song, Yan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_44v1236i8cve4aqslcp2kda8sl